Commentary on NICE technology appraisal guidance on ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia

Heart

Volumn 94, Issue 5, 2008, Pages 643-645

  Armitage, J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BILE ACID SEQUESTRANT; CHOLESTEROL; CYCLOSPORIN A; CYTOCHROME P450; EZETIMIBE; FIBRIC ACID DERIVATIVE; GLUCURONIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; PHYTOSTEROL; PRAVASTATIN; SIMVASTATIN; WARFARIN;

ANGIONEUROTIC EDEMA; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; CORONARY RISK; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG TOLERABILITY; FAMILIAL HYPERCHOLESTEROLEMIA; GASTROINTESTINAL SYMPTOM; HEADACHE; HEALTH CARE ORGANIZATION; HIGH RISK PATIENT; HUMAN; INTESTINE ABSORPTION; LIPID ABSORPTION; LIPID BLOOD LEVEL; LOW DRUG DOSE; MONOTHERAPY; NOTE; PRIORITY JOURNAL; RASH; RECEPTOR UPREGULATION; RISK REDUCTION;

ADULT; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HETEROZYGOTE; HUMANS; HYPERCHOLESTEROLEMIA; LIPIDS; MALE; PRACTICE GUIDELINES AS TOPIC; TECHNOLOGY ASSESSMENT, BIOMEDICAL; TREATMENT OUTCOME;

EID: 42549154342     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2007.137380     Document Type: Note

References (24)

1. National Institute for Health and Clinical Excellence. Ezetimibe for primary (heterozygous-familial and non-familial) hypercholesterolaemia. NICE technology appraisal guidance. London: National Institute for Health and Clinical Excellence, 2007: No 132. Available from http://guidance.nice.org. uk/TA132 (accessed 13 February 2008).
2. Charles Z, Pugh E, Barnett D. Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia: NICE technology appraisal guidance. Heart 2008;94:642-3.
3. Law MR, Wald NJ, Wu T, et al. Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study. BMJ 1994;308:363-6.
4. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths. Lancet 370:1829-39.
5. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
6. Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006;48:438-45.
7. Anonymous. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91(Suppl 5):v1-52.
8. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004;44:720-32.
9. Ryden L, Standi E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28:88-136.
10. National Institute for Health and Clinical Excellence. Statins for the prevention of cardiovascular events TA94. NICE technology appraisal guidance. London: National Institute for Health and Clinical Excellence, 2006: No 94. Available from: http://www.nice.org.uk/TA094 (accessed 13 February 2008).
11. Primatesta P, Poulter NR. Levels of dyslipidaemia and improvement in its management in England: results from the Health Survey for England 2003. Clin Endocrinol (Oxf) 2006;64:292-8.
12. Armitage J. The safety of statins in clinical practice. Lancet 2007;370:1781-90.
13. Bays H. Ezetimibe. Expert Opin Investig Drugs 2002;11:1587-604.
14. Knopp RH, Gitter H, Truitt T, et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003;24:729-41.
15. Sweeney ME, Johnson RR. Ezetimibe: an update on the mechanism of action, pharmacokinetics and recent clinical trials. Expert Opin Drug Metab Toxicol 2007;3:441-50.
16. Bays HE, Moore PB, Drehobl MA, et al. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther 2001;23:1209-30.
17. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002;40:2125-34.
18. Roberts WC. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol 1997;80:106-7.
19. Huff MW, Pollex RL, Hegele RA. NPC1L1: evolution from pharmacological target to physiological sterol transporter. Arterioscler Thromb Vase Biol 2006;26:2433-8.
20. SHARP Collaborative group. SHARP: an international randomized placebo-controlled trial of lipid-lowering in chronic kidney disease - 1 year safety and biochemical efficacy [abstract). J Am Soc Nephrol 2007;18:817A.
21. Davidson MH, Robinson JG. Safety of aggressive lipid management. J Am Coll Cardiol 2007;49:1753-62.
22. Kastelein JJ, Sager PT, de Groot E, et al. Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. Am Heart J 2005;149:234-9.
23. Rossebo AB, Pedersen TR, Allen C, et al. Design and baseline characteristics of the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) Study. Am J Cardiol 2007;99:970-3.
24. Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney lnt Suppl 2003;S207-10.